Cervical Cancer Pipeline Therapeutics Development Review H2 2015

Press Release   •   Dec 14, 2015 07:19 EST

This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Cervical Cancer” addition with 89 market data tables and 16 figures, spread across 348 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

3SBio Inc., Admedus Ltd, Advaxis, Inc., AnGes MG, Inc., Antigen Express, Inc., Arbor Vita Corporation, ArQule, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Azaya Therapeutics, Inc., BIND Therapeutics, Inc., Cancer Research Technology Limited, Cellceutix Corporation, Chong Kun Dang Pharmaceutical Corp., Critical Outcome Technologies Inc., CZ BioMed Corp, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Limited, EirGenix Inc., Eisai Co., Ltd., Epirus Biopharmaceuticals, Inc., EyeGene, Inc., F. Hoffmann-La Roche Ltd., Formune S.L., Genexine, Inc., Genmab A/S, Genor BioPharma Co., Ltd., Genticel S.A., GlaxoSmithKline Plc, Hetero Drugs Limited, Immunovaccine, Inc., Indian Immunologicals Limited, ISA Pharmaceuticals B.V., Karyopharm Therapeutics, Inc., Kite Pharma, Inc., LondonPharma Ltd, Mabion SA, MedImmune, LLC, MEI Pharma, Inc., Mycenax Biotech Inc., Nanotherapeutics, Inc., Nektar Therapeutics, Novartis AG, Oncobiologics, Inc., Oryx GmbH & Co. KG, Otsuka Holdings Co., Ltd., Redbiotec AG, Rexahn Pharmaceuticals, Inc., Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Shantha Biotechnics Limited, Sirnaomics, Inc., Sun Pharma Advanced Research Company Ltd., Taiho Pharmaceutical Co., Ltd., Theravectys SA, Vaccibody AS, VLPbio, Zeria Pharmaceutical Co., Ltd. and Zydus Cadila Healthcare Limited

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)

Drugs Profile Discussed in this Research:

(tegafur + gimeracil + oteracil), AEH-10p, aminolevulinic acid hydrochloride, Antisense Oligonucleotides for Cervical Cancer, Aptamer to Target HPV E7 Protein for Cervical Cancer, ARQ-092, artemether, AV-203, AVC-7, AZD-1775, AZD-5363, bevacizumab, bevacizumab biosimilar, BLI-1004, buparlisib hydrochloride, Cell Therapy for Cervical Carcinoma, Cell Therapy for HPV Associated Cancers, Cell Therapy for HPV-Associated Cancer and Cervical Cancer, Cell Therapy to Target HPV-16 E6 Protein for Cancer, Cell Therapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer, CerviVax, Cervlysis, CIGB-300, CKD-12201, COTI-2, crocetin, dianhydrogalactitol, docetaxel, docetaxel, DPX-E7, durvalumab + tremelimumab, E-7046, EDA-HPVE7, EG-HPV, etirinotecan pegol, everolimus, GSK-2849330, GX-188E, human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar, HuMax-TF-ADC, INO-3112, ISA-101, KM-3174, Lovaxin S, mapatumumab, ME-344, nimotuzumab, NP-001, NTCP-02, OPB-111001, OTAC-DCtag, paclitaxel albumin free, patritumab, pazopanib hydrochloride, Peptides to Inhibit Bcl-x and MCL-1 for Oncology, ProCervix, RA-190, RBT-201, RX-3117, S-009131, selinexor, Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology, SSS-08, STP-909, TA-CIN, TAS-114, Tenacinol, Triapine, TT-12, Vaccine for Cervical Cancer, vaccine for cervical cancer, Vaccine for Cervical Cancer and Genital Warts, Vaccine for Cervical Cancer, Head And Neck Cancer, Vaccine for HPV Associated Cancers, Vaccine for Human papillomavirus Associated Cervical Cancer, Vaccine to Target HIG2, VEGFR-1 and VEGFR-2 for Ovarian Cancer and Cervical Cancer, Vaccine to Target HPV E7 Protein for Cervical Cancer, Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer, VB-1016, Vicoryx, Vvax-001 and Z-100


  • The report provides a snapshot of the global therapeutic landscape of Cervical Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cervical Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cervical Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cervical Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Diseases & treatment Market.

One of the parameters that can define the health of a person is indeed the absence of diseases. There are so many diseases that confront mankind today to make life uncomfortable. If you are the one suffering from a disease and looking ways to get rid of that, the good news is that medical science has the solution for you. There are various treatment methods that are available today to help you cure the disease effectively. There are various diseases & treatment methods that exist today for the better of mankind. Being healthy and enjoying life is really possible today with the evolution of so many treatment methods. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries